CAJ | 학술논문

目的：探讨重组人血小板生成素（rhTPO）对脓毒症血小板减少患者的作用。方法：选取2014年1-12月在本院ICU住院的60例脓毒症合并血小板减少患者作为研究对象，采用随机数字表法将其分为试验组与对照组。在控制感染等综合治疗的基础上，试验组予以rhTPO 300 U/（kg·d），皮下注射，连用7 d，对照组予以同等容量0.9%氯化钠溶液代替rhTPO。记录用药前及用药后第1、2、3、5、7天两组患者血常规、生化指标、凝血指标及输注血小板情况。结果：两组治疗后血小板计数均较治疗前升高，比较差异均有统计学意义（P<0.05）；用药第3、5、7天后试验组的血小板计数明显高于对照组，试验组输注血小板量少于对照组，以上各项比较差异均有统计学意义（P<0.05或P<0.01）。结论：重组人血小板生成素在一定程度上能有效地促进脓毒症血小板减少患者血小板计数的恢复，减少机采血小板输注量，安全可靠，具有较好的血液保护作用。
목적：탐토중조인혈소판생성소（rhTPO）대농독증혈소판감소환자적작용。방법：선취2014년1-12월재본원ICU주원적60례농독증합병혈소판감소환자작위연구대상，채용수궤수자표법장기분위시험조여대조조。재공제감염등종합치료적기출상，시험조여이rhTPO 300 U/（kg·d），피하주사，련용7 d，대조조여이동등용량0.9%록화납용액대체rhTPO。기록용약전급용약후제1、2、3、5、7천량조환자혈상규、생화지표、응혈지표급수주혈소판정황。결과：량조치료후혈소판계수균교치료전승고，비교차이균유통계학의의（P<0.05）；용약제3、5、7천후시험조적혈소판계수명현고우대조조，시험조수주혈소판량소우대조조，이상각항비교차이균유통계학의의（P<0.05혹P<0.01）。결론：중조인혈소판생성소재일정정도상능유효지촉진농독증혈소판감소환자혈소판계수적회복，감소궤채혈소판수주량，안전가고，구유교호적혈액보호작용。
Objective:To explore the effects of Recombinant Human Thrombopoietin (rhTPO) in patients with sepsis-associated thrombocytopenia.Method:60 patients with sepsis-associated thrombocytopenia in the ICU of our hospital from January 2014 to December 2014 were selected and randomly divided into the experimental group and the control group.On the basis of comprehensive treatment such as controlling infections,the experimental group was given rhTPO 300 U/(kg·d) for subcutaneous injection,it was used for 7 days.The control group was given 0.9% sodium chlo-ride injection of the same volume instead of rhTPO.The blood routine,biochemical indexes,blood coagulation indexes and the situation of platelet transfusion in the two groups were compared before treatment and 1, 2, 3, 5 and 7 days after the treatment.Result:After treatment,the PLT of the two groups were higher than before treatment,the differences were statistically significant(P<0.05).3,5 and 7 days after the drug use,the PLT of the experimental group were higher than those of the control group,the transfusion amount of the platelet in the experimental group was lower than that in the control group,the differences in the indexes above were all statistically significant(P<0.05 orP<0.01).Conclusion:Recombinant Human Thrombopoietin(rhTPO) can effectively promote the recovery of sepsis-associated thrombocytopenia,decrease the transfusion amount of machine-gathered blood platelet.This method is safe and reliable,it has a good effect on blood protection.